Lei Y H, Barnes P J, Rogers D F
Department of Thoracic Medicine, National Heart & Lung Institute, London, UK.
Eur J Pharmacol. 1993 Aug 3;239(1-3):257-9. doi: 10.1016/0014-2999(93)91007-a.
Intravenous administration of a K+ channel activator, BRL 38227, inhibited cigarette smoke-induced plasma exudation in guinea pig airways in vivo in a dose-dependent manner with an approximate ED50 of 6 microgram/kg. BRL 38227 also inhibited vagally induced plasma exudation and bronchoconstriction but did not inhibit substance P-induced plasma exudation or neurokinin A-induced bronchoconstriction. K+ channels modulate neurotransmission in the airways and K+ channel activators may have therapeutic potential in bronchial diseases including asthma and chronic bronchitis.